I'll be the first to admit it, I wasn't expecting the strong label requirement. I did expect the drug to be approved early (see my post back in September). I posted on December 14 that I though it was going to happen in the next couple of days. Bottom line is that I'm in for the long haul. I have an average price below $14. I think that anyone who buys in below $20 will be handsomely rewarded over the next 5-years.
The marketing mesage.... "Iclusig: you can use it now, or, unfortunately, you will use it later."
Physicians (and some patients!) currently know that it is the best second line therapy if you're interested in beating CML. And it won't be long until a large percentage of patients know it, BEFORE beginning therapy. First year sales estimates are way too low, and will come in better than 100m. This is an event that is truly disruptive among established oncology markets. Big, big day.